Who is sponsoring NCT04224103?

NCT04224103 is sponsored by Filio Billia.

What drugs are being tested in NCT04224103?

Interventions in NCT04224103: Inhaled nitric oxide.

What condition does NCT04224103 study?

NCT04224103 studies Extracorporeal Membrane Oxygenation, Nitric Oxide, Shock, Cardiogenic.

Is NCT04224103 still recruiting?

NCT04224103 is currently status unknown. Last updated 4 November 2020.

Last reviewed 2020-11-04 · How we verify

NCT04224103: NOVICE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nitric Oxide in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO)

Status unknown Last updated 4 November 2020

What this trial tests

trial testing Inhaled nitric oxide in Extracorporeal Membrane Oxygenation in 10 participants. Status unknown.

Timeline

8 August 2019

Primary endpoint
28 February 2022

28 February 2022

Quick facts

Lead sponsor	Filio Billia
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	10
Start date	8 August 2019
Primary completion	28 February 2022
Estimated completion	28 February 2022
Sites	1 location across Canada

Drugs / interventions tested

Inhaled nitric oxide — full drug profile →

Conditions studied

Extracorporeal Membrane Oxygenation — all drugs for Extracorporeal Membrane Oxygenation →
Nitric Oxide — all drugs for Nitric Oxide →
Shock, Cardiogenic — all drugs for Shock, Cardiogenic →

Sponsor

Filio Billia

Who can join

18 and older, any sex, with Extracorporeal Membrane Oxygenation or Nitric Oxide. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study is designed to investigate the effect of inhaled nitric oxide on cardiac, pulmonary artery, and systemic hemodynamics at various time points during venoarterial extracorporeal membrane oxygenation (VA-ECMO) support. Patients who have been initiated on VA-ECMO will be invited to participate. Inhaled nitric oxide (iNO) will be used early after VA-ECMO cannulation (once consent is obtained). After baseline hemodynamic, biochemical, and echocardiographic parameters are assessed, iNO will be initiated and all parameters will be reassessed after 30 minutes and 6 hours. Inhaled nitric oxide will then be discontinued and all parameters repeated. At the time of VA-ECMO weaning (timing determined by clinical team), iNO will be reinitiated with repeat assessment of hemodynamic, biochemical, and echocardiographic parameters both prior to the wean and after the wean (whether successful or not).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.
Kaddoura R, Elmoheen A, Badawy E, Eltawagny MF, et al · · 2021 · cited 12× · PMID 34350058 · DOI 10.1080/21556660.2021.1930548

Verify or expand the search:

Other trials of Inhaled nitric oxide

Trials testing the same drug.

NCT03873298 — Inhaled NO in IPF and COPD During 6 Minute Walk Test · Phase 2 · unknown
NCT04988932 — Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm · NA · completed

Other recruiting trials for Extracorporeal Membrane Oxygenation

Currently open trials in the same condition.

NCT06862700 — Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients · recruiting
NCT06560164 — Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO · NA · recruiting
NCT06369584 — Prone Position During ECMO in Pediatric Patients With Severe ARDS · NA · recruiting
NCT05574296 — Hydrogen's Feasibility and Safety as a Therapy in ECPR · Phase 1 · recruiting
NCT06660784 — Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04224103 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Filio Billia
Last refreshed: 4 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04224103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing